Three FDA-approved Alzheimer’s drugs targeting amyloid proteins have restored industry confidence in developing treatments for this complex disease. With Alzheimer’s affecting over 7 million Americans and economic costs projected to reach nearly $1 trillion annually by 2050, big drugmakers are racing to capitalize on this therapeutic opportunity. INCLUDED IN THIS TRENDLINE Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs An Alzheimer’s startup emerges with $175M in venture backing GSK ends brain drug alliance with Alector
